Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Summary

This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients will be enrolled into the study. Efficacy and safety of two doses of SHR0302 will be compared to placebo.

Timeline

Start

2022-04-18

Primary completion

2023-10-31

Completion

2024-02-15

Publications

• Zhou C, Yang C, Fan W, Wu J, Yang D, Jin H, Yang Q, Hu G, Lin N, Yang X, Wan J, Zhang J, Wu L, Dai Y, Ma L, Li S, Su J, Sun J, Ding Y, Xiao R, Zhang S, Jiang W, Wang L, Zhang J. Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial. J Am Acad Dermatol. 2026 Jan;94(1):161-171. doi: 10.1016/j.jaad.2025.09.044. Epub 2025 Sep 19.

Drugs

Indications